Skip to content

Erasca, Inc. ERAS Restricted Cash

Restricted Cash at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$4.86M+31.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$0-100%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.28M+59.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$1.34M-37.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$416K

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s restricted cash?
Erasca, Inc. (ERAS) reported restricted cash of $408K in Q1 2026.
How has Erasca, Inc.'s restricted cash changed year-over-year?
Erasca, Inc.'s restricted cash decreased by 0.0% year-over-year, from $408K to $408K.
What is the long-term trend for Erasca, Inc.'s restricted cash?
Over 5 years (2020 to 2025), Erasca, Inc.'s restricted cash has grown at a 5.5% compound annual growth rate (CAGR), from $312K to $408K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.